PRESENTED BY

Navitus Health Solutions, an innovative pharmacy benefits manager (PBM), recently released its 2022 Drug Trend Report, revealing insights on net total cost and utilization trends for its commercial clients. The report highlights an impressive year-over-year trend of 2.6%, considering both specialty and non-specialty products.  Moreover, half of Navitus' commercial clients experienced a decrease in net drug spend compared to 2021.

The report also highlights significant growth in specialty medications, their impact on overall spending, and the strategies employed to control costs. According to IQVIA, specialty medicines now account for 51% of total drug spend, up from 32% in 2021. Despite notable increases in brand drug prices and utilization across various medication categories, Navitus achieved minimal and controlled cost increases for their clients.  While doing so, they delivered real-time savings by favoring clinically appropriate, lowest-cost medications that maximize savings for plan sponsors and health plans and further member affordability.

Founded in 2003, Navitus pioneered an alternative PBM model that broke the traditional mold.  It did not lean on misaligned incentives and drug price opacity widely seen in the PBM marketplace. Navitus' 100% transparent and pass-through model brought forth a lowest net-cost philosophy. Now, twenty years later, when traditional PBM practices of spread pricing are under scrutiny, Navitus' 2022 drug trend report reinforces the outcomes that are achieved when PBMs act in the best interest of their clients and members.